Fungal necrotizing external otitis: diagnosis, management and outcomes of 15 cases.
CT-scan
External otitis
diabetes
fungal
Journal
The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926
Informations de publication
Date de publication:
2022
2022
Historique:
received:
27
11
2020
accepted:
06
08
2022
entrez:
25
11
2022
pubmed:
26
11
2022
medline:
29
11
2022
Statut:
epublish
Résumé
Fungal necrotizing external otitis (NEO) is a rare disease. It is an aggressive and potentially fatal infection. The most commonly reported pathogen is Candida. We aim through this study to share our experience in the management of fungal necrotizing external otitis and discuss its diagnosis tools, anti-fungal treatment choice, and outcomes. We included fifteen patients with diagnosis criteria of fungal NEO; clinical features of NEO with positive culture swabs and/or positive serologic test to a fungal pathogen. The mean age was of 70 years with a prevalence of males. The main symptoms were otalgia (n=15) and otorrhea (n=7). Facial palsy was observed in four cases. Fungal pathogens were Candida(n=10) and Aspergillus (n=5). Complications were observed in eight cases: extension to the temporo-mandibular (n=4), abscess in the retropharyngeal space (n=2), abscess in the parapharyngeal space (n=1) and thrombophlebitis of the internal jugular vein (n=1). Six patients were treated with fluconazole, eight with voriconazole, and one patient with itraconazole. After a mean duration of 52 days of antifungal therapy, fourteen patients have been cured with normalization of the ear symptoms, biological, and imaging features. One patient died of septic shock. No recurrence of the disease was observed after a follow-up of 12 months in all cases.
Identifiants
pubmed: 36425541
doi: 10.11604/pamj.2022.42.306.27168
pii: PAMJ-42-306
pmc: PMC9653543
doi:
Substances chimiques
Antifungal Agents
0
Voriconazole
JFU09I87TR
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
306Informations de copyright
Copyright: Amel El Korbi et al.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Med Mycol Case Rep. 2013 Apr 29;2:113-5
pubmed: 24432231
Eur Arch Otorhinolaryngol. 2006 Jul;263(7):680-4
pubmed: 16633825
Scand J Infect Dis. 2002;34(3):227-9
pubmed: 12030404
Ann Otol Rhinol Laryngol. 2001 Apr;110(4):377-80
pubmed: 11307916
Head Neck. 2000 Jan;22(1):87-9
pubmed: 10585610
N Engl J Med. 2002 Aug 8;347(6):408-15
pubmed: 12167683
Acta Otorhinolaryngol Ital. 2015 Oct;35(5):307-13
pubmed: 26824911
Int J Infect Dis. 2008 Sep;12(5):550-2
pubmed: 18508401
Otolaryngol Head Neck Surg. 1993 Oct;109(4):676-9
pubmed: 8233503
Ann Otol Rhinol Laryngol. 1990 Feb;99(2 Pt 1):117-9
pubmed: 2301865
J Laryngol Otol. 1998 Jan;112(1):98-102
pubmed: 9580133
FEMS Immunol Med Microbiol. 1999 Dec;26(3-4):259-65
pubmed: 10575137
Laryngoscope. 1968 Aug;78(8):1257-94
pubmed: 4970362
Radiology. 1995 Aug;196(2):499-504
pubmed: 7617867
Lancet Infect Dis. 2004 Jan;4(1):34-9
pubmed: 14720566
Scand J Infect Dis. 2003;35(4):284-8
pubmed: 12839164
J Laryngol Otol. 2005 Jan;119(1):71-5
pubmed: 15807974
Antimicrob Agents Chemother. 2009 Mar;53(3):1048-53
pubmed: 19104029
Scand J Infect Dis. 2007;39(4):370-2
pubmed: 17454907